3.6 billion, Kant Lok sold in China! Won 10,000 hospitals on medicine!

Pharmaceutical Network November 16 hearing 3.6 billion! Shanghai Pharmaceutical hand carry money, hand and Kant music signed an agreement!

November 15, Shanghai medicine Announced that its wholly owned subsidiary signed an agreement with Kantor Group to acquire a 100% stake in Kantor Malaysia in cash of 557 million U.S. dollars (3.67 billion yuan). Upon completion of the transaction, Shanghai Pharmaceutical will hold the shares of Kant, Malaysia Business entity in China.

On the same day, Kantor announced that it has signed a definitive agreement to sell its Kantor China business to Shanghai Pharmaceuticals Group Co Ltd for a consideration of US $ 1.2 billion (RMB7.92 billion). It is expected that after obtaining the conditions and regulatory clearance for the corresponding transaction, the transaction will be Concord at the end of fiscal year delivery is completed.

Kant said that the sale of 79.2 billion (RMB conversion, the same below); drug that the acquisition only spent 3.67 billion in cash.

Inconsistencies between the two sides, the medicine in the end spent how much money?

The announcement on the medicine shows that the basic purchase price of this transaction was RMB7.92 billion which will be deducted from the loan amount and liabilities of shareholders and the current cash balance and the adjustment of working capital at the time of delivery The final purchase price is estimated to be approximately 3.67 billion .

In other words, Kant Lok China's overall price is 79.2 billion, but Kant Lok China loans, liabilities, and cash.Shanghai drugs back the loans and liabilities, these are converted to 7.92 billion which finally come true Gold and silver, probably only 3.67 billion.

Like to marry his wife, bride price is 3.67 billion, but to buy a house, do you spend money on a piece of banquet, is 79.2 billion.

79 billion, what medicine bought?

Kantor said the sale includes Kantor's distribution of pharmaceutical and medical products in China, and its staff, infrastructure and systems and processes are expected to be transferred to Shanghai Pharmaceuticals upon completion of the transaction.

But other Kant LOL services in China, including Cordis, the recently acquired patient rehabilitation business, medical equipment purchase Team and other functional departments, did not sell.

On the drug side, said Kant Lok highly accredited China's existing team, and will be happy to see its retention.It is reported that there will be more than two thousand Kant music staff transferred to the drug.

However, Kant Lok announced that Mr. Karl Fung, Chairman of K & L China, will be retired and effective immediately.

In fact, in July this year, Kant told China that it is going to sell the news.

At that time, Sinopharm, China Resources and Shangyou both participated in the bidding. The top three among the "Top 100 National Drug Approved by the Ministry of Commerce" all want to swallow the Kant Lok ranked No. 8 and finally spend the drug, 'The second position, will be replaced by the drug.

Kantian China's 14 direct sales companies, 17 distribution operations centers, distribution networks covering 322 cities, nearly 11,000 healthcare facilities, and 30 DTP pharmacies owned by Kant Lladro are owned by the company.

According to the company's annual report for 2016, Kantor China reported a revenue of 25.402 billion yuan a year, plus 120.765 billion yuan on drugs, surpassing CRC's revenue of 139.3 billion yuan in 2016.

According to the data of the "Top 100 Pharmaceuticals Top 100 Revenue" issued by the Ministry of Commerce in the "Statistical Report on the Operation of the Pharmaceutical Circulation Industry in 2016", the data of Shanghai Pharmaceutical and Kant Lok China also surpassed that of China Resources - but the number one Sinopharm, the gap is quite far away.

However, the acquisition of 'the country's largest imported pharmaceuticals proxy One of the business' Kant Lok China, the drug a solid position, will become China's largest importer drug Agents.